Uppsala, Sweden — Olink Bioscience have today announced that they have expanded their patent portfolio within the field of rolling circle amplification by acquir-ing a family of three patents from the Danish biotech company In Situ RCP A/S.

The acquired portfolio contains patents relevant to target primed rolling circle amplification and methods for amplification of circular molecules. Rolling circle amplification is a method increasingly used for nucleic acid amplification as well as in the fields of nucleic acid and protein analysis.

“Olink Bioscience is currently exploring novel products and expansion of our proprietary Duolink® product series. The acquisition of these patents is an important step in the proc-ess to further strengthen our already strong position within the field of DNA-based immuno-assays, as well as to allow us to expand into novel areas of nucleic acid based analysis based on rolling circle amplification” says Mats Gullberg, CTO of Olink Bioscience.

The Duolink product line is based on Olink Bioscience proprietary in situ PLA™, a proximity ligation assay technology that extends the capabilities of traditional immunofluorescence and immunohistochemistry to include direct detection of proteins, protein interactions and modifications with unparalleled specificity and sensitivity. Target proteins are detected with single molecule resolution, allowing digital quantification and information about the exact localization of the target. Furthermore, the proteins can be studied at normal expression lev-els in fixed cells and tissue sections.

About Olink Bioscience

Olink Bioscience is a privately held biotech supply company based in Uppsala, Sweden founded in 2004. The company controls significant IP covering technologies related to de-tection and analysis of proteins and nucleic acids. These technologies are commercialized as proprietary Olink Bioscience products, in spin-out companies and in collaboration with external organization. In 2007 Olink Bioscience introduced the Duolink product line for in situ detection of proteins, protein interactions and protein modifications. These products are based on PLA, a proximity ligation assays technology which use dual recognition of the analyte in combination with a DNA amplification based reporter system, resulting in unparal-leled sensitivity and specificity. The technology is available as reagent kits and contract re-search projects through Olink Bioscience.

Duolink is intended for research use only. Duolink is not for use in human diagnostic or therapeutic procedures.

For information please contact:

Mats Gullberg

Chief Technology Officer Olink Bioscience

Phone: +46 (0) 18 444 39 80 email: mats.gullberg@olink.com